A Phase II Study of First-Line Eribulin Mesylate for Locally Recurrent or Metastatic HER2-Negative Breast Cancer


A Phase II Study of First-Line Eribulin Mesylate for Locally Recurrent or Metastatic HER2-Negative Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Lisa A Carey, MD (2/25/13)

Vahdat L et al. Results of a Phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract P1-12-02.

Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.